Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1

Conditions

Melanoma 273Carcinoma, Non-Small-Cell Lung 244Carcinoma, Renal Cell 144Neoplasms 99Neoplasm Metastasis 99Squamous Cell Carcinoma of Head and Neck 88Carcinoma, Hepatocellular 87Colorectal Neoplasms 82Lung Neoplasms 77Stomach Neoplasms 59Pancreatic Neoplasms 56Carcinoma, Transitional Cell 50Hodgkin Disease 47Urinary Bladder Neoplasms 42Head and Neck Neoplasms 42Breast Neoplasms 40Ovarian Neoplasms 37Triple Negative Breast Neoplasms 34Small Cell Lung Carcinoma 33Brain Neoplasms 33Sarcoma 32Prostatic Neoplasms 32Glioblastoma 32Kidney Neoplasms 29Recurrence 28Multiple Myeloma 25Esophageal Neoplasms 24Uveal Melanoma 23Skin Neoplasms 23Uterine Cervical Neoplasms 22

Interventions

Paclitaxel 3Bevacizumab 3fludarabine 2Nivolumab 2Gemcitabine 2Carboplatin 2rucaparib 1pembrolizumab 1liposomal doxorubicin 1dostarlimab 1Taxes 1Sunitinib 1Stem Cell Transplantation 1Sirolimus 1Radiotherapy 1Melphalan 1Ipilimumab 1Immunoglobulin G 1Erlotinib Hydrochloride 1Doxorubicin 1Docetaxel 1Disulfides 1Dexamethasone 1Celecoxib 1Capecitabine 1Busulfan 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenocarcinoma, Clear Cell × Nivolumab × Clear all
NCT03355976 2026-04-02

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Brown University

Phase 2 Active not recruiting
46 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Adenocarcinoma, Clear Cell

NCT03241745 2024-12-27

A Study of Nivolumab in Selected Uterine Cancer Patients

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
35 enrolled 8 charts
GynecologicSarcoma

Carcinosarcoma, Leiomyosarcoma, Uterine Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡